Results 91 to 100 of about 137,029 (384)

Infliximab in inflammatory bowel disease

Therapeutic Advances in Chronic Disease, 2019
Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD.
K. Papamichael, S. Lin, M. Moore, Garyfallia Papaioannou, Lindsey Sattler, A. Cheifetz   +5 more
semanticscholar   +1 more source

Therapeutic targeting of myeloid cells in liver fibrosis: Mechanisms and clinical prospects

Animal Models and Experimental Medicine, EarlyView.
This review systematically summarizes the origin, recruitment, and differentiation regulation mechanisms of myeloid cells in driving hepatic fibrosis progression. By targeting these three critical phases, potential therapeutic strategies for liver fibrosis can be explored.
Yue Wang, Yiming Liu, Dan Chen, Leiming Liu, Leimin Sun, Lingling Zhang   +5 more
wiley   +1 more source

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

BMJ Open
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and ...
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright   +24 more
doaj   +1 more source

Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. [PDF]

PLoS ONE, 2014
AIM: To assess the endoscopic activity and Clinical activity after a one-year period of infliximab therapy and to evaluate the association between mucosal healing and need for retreatment after stopping infliximab in patients with Inflammatory bowel ...
Cong Dai, Wei-Xin Liu, Min Jiang, Ming-Jun Sun   +3 more
doaj   +1 more source

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +1 more source

Acute brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors [PDF]

, 2015
Introduction: There is limited data in the literature about brucellosis related to an intracellular pathogen and anti-tumor necrosis factor alpha (anti-TNFα) medication.
Akalın, Ş., Demirkan, N., Ergin, Ç., Kutlu, Murat, Sayin-Kutlu, S., Zorbozan, O., Çobankara, V., Şahin, B., Şen-Türk, N.   +8 more
core   +1 more source

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment [PDF]

Journal of Crohn's and Colitis, 2014
The anti-TNF antibody infliximab is effective in inducing remission in Crohn's disease as well as in ulcerative colitis and many patients are treated for several years with sustained clinical remission. However, the role of monitoring s-infliximab and antibodies towards infliximab during maintenance treatment remains unclear.
Michael Eberhardson, Ragnar Befrits, Per Marits, Laura Landucci, Jakob Nilsson, Ann-Charlotte Wikström, Loa Davidsdottir, Ulf Sundin   +7 more
openaire   +3 more sources

Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System—A Multicenter Cohort Study in 163 Patients

Annals of Neurology, EarlyView.
Objective The aim was to determine patient, disease, and treatment characteristics associated with outcome in patients with primary angiitis of the central nervous system (PACNS) in a large multicenter German cohort. Methods In a retrospective, observational cohort study, we analyzed 163 adult patients who met the diagnostic criteria for PACNS.
Anna Lena Fisse, Nadine Bonberg, Carolin Beuker, Claudia Pfeuffer, Andreas Heidenreich, Christina Krüger, Milani Deb‐Chatterji, Jana Becker, Stefan T. Gerner, Clemens Küpper, Louisa Nitsch, Roxane‐Isabelle Kestner, Lars Udo Krause, Juliane Herm, Alexander Katalinic, André Karch, Ralf Gold, Heinz Wiendl, Wolf‐Rüdiger Schäbitz, Gabor C. Petzold, Waltraud Pfeilschifter, Marius Ringelstein, Thorsten R. Doeppner, Lars Kellert, Hagen B. Huttner, Markus Kraemer, Tim Magnus, Karl Georg Haeusler, Heike Minnerup, Jens Minnerup   +29 more
wiley   +1 more source

Recent advances: rheumatology [PDF]

, 2000
No abstract ...
Capell, H.A., Kerr, H., Madhok, R.
core   +6 more sources

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source